| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |